Articles related to TARGETED THERAPIES

Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.

To help patients and clinicians in strategizing about care decisions at the individual level, ASH convened a multidisciplinary panel — which included experts and patient representatives — to form standardized guidelines for newly diagnosed AML in older patients.

Dr. Rita Rao shares her expert perspective on the goals of neoadjuvant therapy, treatment selection, and the evolving landscape of HER2-targeted strategies.

When glutamate binds to the cancer cells’ NMDA receptors, a channel opens and calcium flows into the cell. This influx triggers molecular signaling cascades that drive tumor growth and metastasis.

Patients on rilonacept experienced more days with no or minimal pericarditis symptoms (81% vs. 25%; p < 0.001) and more persistent clinical response at 16 weeks (81% vs. 20%; p < 0.001) compared with placebo.

Patients whose disease has progressed on osimertinib or other EGFR tyrosine kinase inhibitors (TKIs) without emergent T790M or other targetable alterations can receive platinum-based chemotherapy with or without amivantamab.